Razvoj i karakterizacija mukoadhezivnih flastera salbutamol sulfata za jednosmjernu bukalnu isporuku by AYRIVAN PURATCHIKODY et al.
Adequate absorption and transport of drugs in the body is the ultimate aim of opti-
mal drug delivery systems. Peroral administration of drugs, the preferred route of drug
administration by both clinicians and patients, has several disadvantages, such as he-
patic first pass metabolism, longer onset of action and enzymatic degradation of drugs
within the GI tract. Mucoadhesive buccal drug delivery systems have currently become
an interesting topic for drug delivery research owing to their potential to optimize local-
ized drug delivery, by retaining dosage forms at the site of action or within the absorp-
tion site (1). Buccal mucosa is well supplied with both vascular and lymphatic circula-
tion and drug administered through buccal mucosa can circumvent first-pass hepatic
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Buccal patches of salbutamol sulfate were prepared us-
ing five different water soluble polymers in various pro-
portions and combinations using PEG-400/PG as plasti-
cizers. A 32 full factorial design was used to design the
experiments for each polymer combination. Patches were
laminated on one side with a water impermeable back-
ing layer for unidirectional drug release. The thickness of
medicated patches ranged between 0.2 and 0.4 mm and
showed an increase in mass whenever PEG-400 was used
as plasticizer. The surface pH of all patches approached
neutral. Eight formulations which had shown high fold-
ing endurance (> 300) were selected for evaluation. Pat-
ches prepared with PEG-400 showed a high swelling in-
dex. The residence time of the tested patches ranged bet-
ween 105 and 130 min. Formulations A10, A32, B10 and
B32 fitted the Higuchi model best, whereas formulations
A19 and B19 showed super case II transport drug release.
Stability studies indicated that there was no change in the
chemical and physical characteristics during the test period
of 6 months.
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metabolism and pre-systemic elimination in the gastrointestinal tract (2). The large abso-
lute surface area of the oral cavity contributes to rapid and extensive drug absorption.
Also, buccal drug delivery occurs in a tissue that is more permeable than skin and is less
variable between patients, resulting in lower inter-subject variability. Moreover, buccal
drug absorption can be promptly terminated in case of toxicity by removing the dosage
form from the buccal cavity. It is also possible to administer drugs to patients who can-
not be dosed orally (2).
Previously, studies have been carried out to formulate various mucoadhesive buccal
drug delivery devices, including tablets (3), films (4), patches (5), disks (6), ointments (7)
and gels (8). Among these formulations, buccal patches are preferred owing to their good
flexibility compared to tablets and more accurate dosing of the drug in comparison with
gels and ointments.
Asthma and chronic obstructive pulmonary disease (COPD) are among the most pre-
valent diseases on the earth (9). Salbutamol sulfate (SS) is a short-acting b2-adrenergic
receptor agonist used for the relief of bronchospasm in conditions such as asthma and
COPD. SS is readily absorbed from the GI tract and undergoes the first pass metabolism
in the liver and possibly in the gut wall. The plasma half-life of this drug is 4 to 6 hours
and thus it requires multiple dosing a day (10). Mucoadhesive buccal patches of SS which
bypass the hepatic metabolism and release the drug at a desired rate may have distinct
advantages over conventional dosage forms. The physicochemical and pharmacokinetic
profiles of SS make it a suitable candidate for the preparation of a buccal adhesive drug
delivery system. Therefore, the aim of the present study was to develop unidirectional
mucoadhesive buccal patches of SS to ensure satisfactory drug release, and to prevent
the first pass metabolism and improve bioavailability.
EXPERIMENTAL
Materials
Salbutamol sulfate was obtained as a gift sample from Dr. Reddy’s Laboratories, In-
dia. The polymers hydroxypropyl methyle cellulose (HPMC), polyvinyl alcohol (PVA),
Carbopol 934p (Cp), sodium carboxymethylcellulose (NaCMC), polyvinyl pyrolidine (PVP
K30) were procured from Sigma Chemicals, USA. Agar, methanol, sodium saccharinate,
sodium hydroxide, potassium dihydrogen phosphate, polyethylene glycol 400 (PEG-400)
and proplylene glycol (PG) were purchased from Merck, India. Biaxially-oriented poly-
propylene (BOPP) film was supplied by Pidilite, India. Fresh pig buccal mucosa was ob-
tained from a local slaughterhouse and was used within 2 hours of slaughter.
Methods
Formulation of mucoadhesive buccal patches. – The buccal mucoadhesive patches of SS
were prepared by the solvent casting technique using water as solvent (11). Different po-
lymer combinations were tried out (HPMC/PVA/Cp, HPMC/PVA/NaCMC, PVA/
NaCMC/ Cp and PVA/NaCMC/PVP). A 32 full factorial design (Design Expert, Version
7, Stat-Ease Inc, Minneapolis, MN) was used to design the experiments for each polymer
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combination. Aqueous polymer solutions of different concentrations were mixed in dif-
ferent ratios as mentioned in Table I. The above polymer solutions were mixed with 2
mL of PG or PEG on a magnetic stirrer, at low rpm, for a period of 1 hour to get a ho-
mogenous clear solution. To this mixture, a drug solution corresponding to 230.4 mg was
added and mixed thoroughly. This solution was then poured into a specially fabricated
Teflon® coated circular dish (9.6 cm diameter). Patches were then allowed to dry at room
temperature for 2 hours and were further dried for 36 hrs at 60 oC in a hot air oven.
Finally, the patches were vacuum dried for 4 hours at room temperature in a vacuum
desiccator. After careful examination, the dried patches were removed, checked for any
imperfections or air bubbles and cut into 2 cm diameter patches using a specially fabri-
cated circular stainless steel cutter. The patches were laminated on one side with a water
impermeable backing layer (Pidilite® BOPP film). The samples were packed in alumi-
nium foil and stored in a glass container at room temperature.
Evaluation of patches. – Mass uniformity, thickness and folding endurance were de-
termined for the patches without a backing membrane. Mass uniformity and thickness
were tested in 3 different, randomly selected, individual patches from each batch using
an electronic balance and a standard screw gauge, respectively. Folding endurance of the
patches was determined by repeatedly folding one patch at the same place till it broke or
folded up to 300 times without breaking (12).
For drug content evaluation, the medicated patch (without backing membrane) was
allowed to dissolve in 10 mL of simulated saliva solution (pH 6.2) for 2–3 hours under
occasional shaking. The resultant solution was filtered through 0.46-mm filter paper and
after suitable dilution, the amount of SS present in the patch was determined spectro-
photometrically at 278 nm (Shimadzu 1800, Japan)
Surface pH of the buccal patches (without backing membrane) was determined by a
modified method reported by Bottenberg et al. (13). Buccal patches were left to swell for
2 hours on the surface of an agar plate, prepared by dissolving 2 % (m/V) agar in war-
med isotonic phosphate buffer (pH 6.75) under stirring and then pouring the solution
into a Petri dish till it gelled at room temperature. The surface pH was measured by bring-
ing a combined glass electrode in contact with the surface of the patch, allowing it to
equilibrate for 1 minute. The experiment was repeated thrice and the average was taken.
During the swelling studies, the diameter of the original patch (without backing mem-
brane) was determined first (2 cm). Then the sample was allowed to swell on the surface
of an agar plate (prepared as described in the measurement of surface pH section) kept
in an incubator maintained at 37 °C. Measurement of the swollen patch diameter was
carried out at predetermined time intervals for 90 minutes (11).
Residence time (ex vivo mucoadhesion time)
The ex vivomucoadhesion (residence) time was determined using a locally modified
USP 23 (Erweka ZT72) disintegration apparatus (14, 15). In the current study, pig mu-
cosa was used as the mucosal membrane because pig buccal membrane closely resem-
bles the human buccal membrane in structure and permeability. The mucosal membrane
was separated by removing the underlying fat and loose tissues. The membrane was
washed with distilled water and then with simulated saliva (pH 6.2) at 37 °C. Pig buccal
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A1 B1 15.0 10.0 5.0
10.0
A2 B2 13.8 9.2 6.9
A3 B3 12.8 8.6 8.6
A4 B4 12.9 12.9 4.3
A5 B5 12.0 12.0 6.0
A6 B6 11.3 11.3 7.5
A7 B7 11.3 15.0 3.8
A8 B8 10.6 14.1 5.3
A9 B9 10.0 13.3 6.7
A10 B10 15.0 10.0 5.0
A11 B11 12.9 8.6 8.6
A12 B12 11.3 7.5 11.2
A13 B13 12.9 12.9 4.3
A14 B14 11.3 11.2 7.5
A15 B15 10.0 10.0 10.0
A16 B16 11.3 15.0 3.6
A17 B17 9.9 13.3 6.7
A18 B18 9.0 12.0 9.0
A19 B19 15.0 7.5 7.5
A20 B20 12.0 6.0 12.0
A21 B21 10.0 5.0 15.0
A22 B22 13.3 10.1 6.7
A23 B23 10.9 8.1 10.9
A24 B24 9.2 6.9 13.9
A25 B25 12.0 12.0 6.0
A26 B26 10.0 10.0 10.0
A27 B27 8.6 8.6 12.9
A28 B28 10.0 10.0 10.0
A29 B29 7.5 15.0 7.5
A30 B30 6.0 18.0 6.0
A31 B31 15.0 7.5 7.5
A32 B32 12.0 12.0 6.0
A33 B33 10.0 15.0 5.0
A34 B34 18.0 6.0 6.0
A35 B35 15.0 10.0 5.0
A36 B36 12.9 12.9 4.3
a A1-A36: plasticizer used is PEG 400 (2 mL); B1-B36: plasticizer used is PG (2 mL).
b Total volume of polymer solution added excluding plasticizer and drug solution was 30 mL.
mucosa, 3 cm long, was glued to the surface of a glass slide. One side of the patch was
wetted with one drop of simulated saliva (pH 6.2) and pasted to the pig buccal mucosa
by applying a light force with a fingertip for 20 seconds. The glass slide was vertically
fixed to the disintegration apparatus and allowed to move up and down (25 times per
min) so that the patch was completely immersed in the buffer solution at the lowest
point and was out at the highest point. The beaker was filled with 800 mL of simulated
saliva (pH 6.2) and was kept at 37 ± 1 °C. The time required for the patch to detach from
the buccal mucosa was recorded as the mucoadhesion time. The experiment was re-
peated thrice and the average was taken.
In vitro drug dissolution
The dissolution study was carried out using a USP 23 Type-2 rotating paddle disso-
lution test apparatus (Electrolab, EDT-08Lx) (14). The dissolution medium used was 100
mL of simulated saliva solution (pH 6.2) at 37 ± 5 °C, which was stirred at 50 rpm. The
patch of 2-cm diameter was fixed onto the glass disk with the help of cyanoacrylate ad-
hesive. The disk was put at the bottom of the dissolution vessel so that the patch re-
mained on the upper side of the disk. Samples (4 mL) were withdrawn at pre-determi-
ned time intervals (5, 10, 15, 30, 45, 60, 90, 120, 150 and 180 min) and replaced with an
equal volume of dissolution medium. The samples were filtered through a 0.45-mm filter
and appropriately diluted with simulated saliva solution (pH 6.2) and assayed spectro-
photometrically at 278 nm. The mechanism of drug release from the buccal patches was
determined by finding the best fit of the release data to Higuchi and Korsmeyer-Peppas
plots (16, 17). The release rate constants k and n of each model were calculated by linear
regression analysis. Coefficients of determination (R2) were used to evaluate the accu-
racy of the fit.
In vitro drug permeation
The in vitro buccal permeation of SS was studied through the pig buccal mucosa us-
ing a Franz-diffusion cell. The tissue preparation was similar to that explained previ-
ously. Freshly obtained buccal mucosa was mounted between the donor and receptor
compartments so that the smooth surface of the mucosa faced the donor compartment.
The patch was placed on the mucosa and the compartments were clamped together. The
donor compartment was slightly wetted with 1 mL of simulated saliva. The receptor
compartment was filled with isotonic phosphate buffer pH 7.4. The diffusion cell was
thermostated at 37 ± 2 °C and the receptor compartment was stirred at a rate of 100 rpm
(14, 18). One mL sample was withdrawn at pre-determined time intervals using a butter-
fly canula and syringe. The buffer was immediately replaced using blank pre-warmed
buffer. After filtration through 0.45-mm filter and appropriate dilution, the samples were
analyzed for the drug content at 278 nm.
Accelerated stability studies and stability in human saliva
Selected patches were subjected to accelerated stability testing by wrapping them in
aluminium foil and packing in glass vials. These patches were kept in an incubator
maintained at 37 ± 0.5 °C and 75 ± 5 % RH for 6 months. Changes in the appearance
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(color, shape), residence time and drug content of the stored patches were investigated
after 1, 2, 3, 5 and 6 months. The data presented were the mean of three determinations.
Stability of the selected patches was assessed in natural human saliva collected from
healthy human adult volunteers. Patches were placed in separate Petri dishes containing
5 mL of human saliva and kept in a temperature-controlled oven at 37 ± 0.2 °C.
RESULTS AND DISCUSSION
Formulation of mucoadhesive buccal patches
In the present study, buccal patches of SS were prepared by different polymer com-
binations of HPMC, PVA, Cp, NaCMC and PVP using the solvent casting method. A to-
tal of 72 formulations were prepared in triplicate using a 32 factorial design. Factorial de-
sign was used only to design the experiments. PG or PEG-400 were used as plasticizers.
Impermeable backing membrane is an essential part of a buccal mucoadhesive pa-
tch to obtain unidirectional drug flow. Backing membrane prevents loss of the drug at
the required site and also minimizes the exposure of other tissues to the drug by pre-
venting bidirectional flow. Many authors have used ethyl cellulose as a backing mem-
brane but reports have shown some permeability. Also, laminating the patches with ethyl
cellulose film was not completely successful (19). Therefore, in the current study, we have
used the BOPP film as a backing membrane.
One of our major aims during the formulation step was to avoid use of organic sol-
vents to prevent any unwanted residual solvent complications in vivo. Use of water as a
solvent was the reason for the long duration of drying time during the formulation step
(36 hours).
Mass, thickness, folding endurance, drug content and surface pH
Physicochemical characteristics of the medicated patches are shown in Table II. The
prepared patches were smooth, uniform in thickness, mass, drug content and showed no vi-
sible cracks or folds. The thickness of the medicated patches ranged between 0.2 ± 0.002 and
0.4 ± 0.01 mm, and the mass of the patches varied between 42.7 ± 2.8 and 85.19 ± 2.1 mg.
It was noticed that the mass of the patches increased with PEG 400 as plasticizer. The
surface pH of all the patches ranged from 6–7 and hence no mucosal irritation was ex-
pected. The patches showed favorable drug loading which varied between 8.3 ± 0.4 and
9.7 ± 0.4 mg per 2 cm–2 patches (i.e., drug loading efficacy of 83 to 97 %). All patches
showed satisfactory folding endurance of >150. Of these 72 formulations eight patches
(A1, A10, A19, A32, B2, B10, B19 and B32) showed high folding endurance of over 300.
Therefore these patches were selected for further evaluations.
Swelling studies
Swelling behavior of selected SS patches as a function of time is illustrated in Fig. 1.
The swelling indices of the patches were high (up to 62 ± 4 for A10 at the end of 90 min)
and varied between the formulations. Higher swelling indices may be due to the presen-
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A1 73.3 ± 5.8 0.4 ± 0.00 >300 9.0 ± 0.8 6.3
A2 70.4 ± 4.2 0.3 ± 0.00 175 9.1 ± 0.7 6.5
A3 76.8 ± 2.8 0.3 ± 0.01 180 8.5 ± 0.7 6.7
A4 72.6 ± 1.8 0.4 ± 0.00 150 8.8 ± 0.8 7.0
A5 75.3 ± 3.7 0.4 ± 0.01 198 9.0 ± 0.9 6.0
A6 76.5 ± 8.5 0.3 ± 0.01 220 8.6 ± 0.5 6.4
A7 74.1 ± 6.4 0.3 ± 0.01 194 8.5 ± 0.4 7.0
A8 72.2 ± 6.4 0.4 ± 0.01 188 9.1 ± 0.7 6.3
A9 75.4 ± 4.3 0.3 ± 0.01 178 9.1 ± 0.6 6.5
A10 83.3 ± 5.8 0.4 ± 0.01 >300 9.3 ± 0.6 6.1
A11 82.5 ± 2.4 0.4 ± 0.01 199 9.0 ± 0.5 6.5
A12 84.2 ± 2.7 0.3 ± 0.01 187 8.6 ± 0.4 6.6
A13 85.2 ± 2.1 0.4 ± 0.01 172 8.5 ± 0.4 7.0
A14 81.6 ± 5.8 0.4 ± 0.01 200 8.9 ± 0.7 6.4
A15 82.5 ± 3.3 0.2 ± 0.01 168 8.9 ± 0.6 6.4
A16 84.4 ± 4.3 0.3 ± 0.01 182 9.0 ± 0.6 6.8
A17 82.0 ± 3.4 0.2 ± 0.01 195 9.1 ± 0.8 6.7
A18 84.9 ± 7.2 0.4 ± 0.01 188 9.0 ± 0.6 6.5
A19 63.3 ± 8.3 0.4 ± 0.01 >300 9.5 ± 0.8 6.2
A20 64.9 ± 2.6 0.3 ± 0.01 197 9.0 ± 0.6 6.4
A21 65.6 ± 4.3 0.3 ± 0.01 176 8.8 ± 0.8 6.8
A22 62.5 ± 3.7 0.4 ± 0.01 165 8.7 ± 0.6 6.4
A23 65.8 ± 3.2 0.4 ± 0.01 186 8.3 ± 0.4 6.5
A24 63.5 ± 1.4 0.4 ± 0.01 197 8.5 ± 0.6 6.8
A25 63.8 ± 3.4 0.4 ± 0.01 172 8.6 ± 0.7 7.0
A26 62.0 ± 7.2 0.4 ± 0.01 168 9.0 ± 0.7 6.4
A27 64.5 ± 5.5 0.2 ± 0.01 241 8.8 ± 0.6 6.1
A28 75.0 ± 5.1 0.3 ± 0.01 186 8.6 ± 0.5 6.8
A29 74.1 ± 5.4 0.4 ± 0.01 200 8.9 ± 0.7 6.7
A30 76.2 ± 7.8 0.4 ± 0.01 195 9.0 ± 0.7 6.6
A31 74.2 ± 6.2 0.4 ± 0.01 165 9.0 ± 0.6 6.4
A32 79.9 ± 6.2 0.4 ± 0.01 >300 9.1 ± 0.5 6.4
A33 78.5 ± 5.1 0.3 ± 0.01 172 9.1 ± 0.6 6.3
A34 79.3 ± 4.3 0.3 ± 0.01 187 8.8 ± 0.5 6.8
A35 77.2 ± 6.7 0.4 ± 0.01 184 8.5 ± 0.7 6.6
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A36 76.5 ± 5.8 0.2 ± 0.01 169 8.9 ± 0.6 6.5
B1 42.8 ± 8.7 0.4 ± 0.01 196 9.0 ± 0.7 6.4
B2 45.0 ± 4.2 0.4 ± 0.01 >300 9.3 ± 0.8 6.3
B3 43.3 ± 3.4 0.4 ± 0.01 200 9.0 ± 0.6 6.3
B4 42.7 ± 2.8 0.3 ± 0.01 169 9.1 ± 0.7 6.8
B5 44.3 ± 1.8 0.2 ± 0.01 199 9.1 ± 0.7 6.2
B6 46.2 ± 6.4 0.4 ± 0.01 249 8.5 ± 0.6 6.4
B7 43.8 ± 3.5 0.4 ± 0.01 158 8.6 ± 0.7 6.3
B8 44.6 ± 1.9 0.4 ± 0.01 188 8.6 ± 0.6 6.3
B9 44.3 ± 1.6 0.4 ± 0.01 188 8.8 ± 0.6 6.4
B10 50.0 ± 8.1 0.3 ± 0.01 >300 9.6 ± 0.2 6.4
B11 49.5 ± 7.4 0.4 ± 0.01 186 9.1 ± 0.7 6.5
B12 48.3 ± 4.6 0.2 ± 0.01 198 9.1 ± 0.5 6.0
B13 49.8 ± 7.7 0.4 ± 0.01 194 8.9 ± 0.6 6.8
B14 47.8 ± 4.5 0.3 ± 0.01 187 9.0 ± 0.7 6.5
B15 47.6 ± 4.2 0.4 ± 0.01 197 8.9 ± 0.7 6.8
B16 46.0 ± 7.1 0.4 ± 0.01 186 9.1 ± 0.8 6.7
B17 46.8 ± 7.3 0.3 ± 0.01 192 9.0 ± 0.6 6.9
B18 42.9 ± 7.1 0.4 ± 0.01 191 9.0 ± 0.7 6.5
B19 50.0 ± 2.7 0.3 ± 0.01 >300 9.2 ± 0.6 6.4
B20 49.3 ± 2.7 0.2 ± 0.01 199 9.0 ± 0.8 6.3
B21 48.5 ± 6.1 0.4 ± 0.01 188 9.1 ± 0.8 6.6
B22 49.5 ± 4.6 0.4 ± 0.01 177 8.5 ± 0.6 6.8
B23 53.6 ± 3.2 0.4 ± 0.01 182 8.8 ± 0.8 6.8
B24 51.1 ± 2.8 0.4 ± 0.01 225 9.1 ± 0.7 6.4
B25 50.1 ± 3.0 0.4 ± 0.01 167 9.1 ± 0.6 6.6
B26 54.9 ± 2.6 0.4 ± 0.01 186 9.0 ± 0.6 6.4
B27 55.8 ± 3.4 0.4 ± 0.01 199 9.0 ± 0.6 6.7
B28 54.3 ± 1.8 0.3 ± 0.01 165 8.9 ± 0.4 6.8
B29 55.5 ± 4.8 0.2 ± 0.01 199 9.0 ± 0.8 6.8
B30 53.5 ± 2.2 0.3 ± 0.01 197 9.1 ± 0.4 6.3
B31 54.2 ± 5.4 0.4 ± 0.01 188 9.0 ± 0.6 6.5
B32 55.4 ± 3.5 0.4 ± 0.01 >300 9.7 ± 0.4 6.3
B33 53.2 ± 4.8 0.4 ± 0.01 197 9.0 ± 0.8 6.3
B34 52.1 ± 8.4 0.3 ± 0.01 197 8.9 ± 0.7 6.8
B35 53.4 ± 1.5 0.4 ± 0.01 233 8.5 ± 0.6 6.4
B36 54.3 ± 5.4 0.4 ± 0.01 200 9.0 ± 0.8 6.5
a Mean ± SD, n = 3.
b Mean, n = 3.
ce of water soluble polymers. The swelling behavior provides an indication of the rela-
tive moisture absorption capacities of polymers and whether the formulations maintain
their integrity after absorption of moisture. Differences in swelling of the tested hydro-
philic polymers could be explained by the difference in resistance of the matrix network
structure (hydrogen bond) to the movement of water molecules. In addition, the pres-
ence of a water-soluble drug might have improved the surface wetting of the matrix.
The swelling indices increased in the following order: B10<B32<B2<B19<A19<A32<A1<
A10. It was seen that patches with PEG-400 showed more swelling compared to those
with PG. This index even reached a maximum value of 62 for formulation A10 after 90
min. This could be due to higher water uptake of PEG-400 compared to PG. The pres-
ence of PEG-400 could have altered the water distribution within such systems and the-
reby modified the polymer matrix structure (20). Even though the swelling indices were
high, the patches did not show any appreciable changes in shape and form and main-
tained their integrity during the study period.
Residence time (ex vivo mucoadhesion time)
The values of ex vivo mucoadhesion time are presented in Fig. 2. The residence time
of the tested patches ranged between 105 and 130 min. Previous studies reported no re-
lation between mucoadhesion strength and mucoadhesion time (18). However, none of
the patches were detached from the mucosal membrane over the study period, which in-
dicated that the bioadhesion of all patches was sufficient to retain the patch on the
buccal mucosa.
In vitro drug dissolution
In vitro release of SS from different patches is shown in Fig. 3. The maximum in vitro
release was evaluated to be 101.3 ± 1.8 % over a period of 60 min for formulation A10.
This finding was also in agreement with the swelling studies where A10 showed the ma-
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Fig. 1. Swelling behavior of selected SS patches. Mean ± SD, n = 3.
ximum swelling index. Formulations A1, B2, B10 and B32 showed maximum drug re-
lease after 45 min, A10, A32, B19 showed maximum drug release after 60 min and A19
showed maximum drug release after 90 min. Faster drug release can be correlated with
the high swelling indices observed in this study. From the drug release profile we could
not detect any relation between the drug release and polymer composition. From an ini-
tial examination, the drug release profile of all patches showed an erratic drug release,
which was not appropiate for a controlled drug delivery system. The drug release mech-
anism from controlled release devices is very complex, and not yet completely under-
stood. Although some processes may be classified as either purely diffusional or purely
erosion controlled, many others can only be interpreted as being governed by both.
The R2, k and n values are given in Table III. Formulations A10, A32, B10 and B32
provided good fit to the Higuchi model. According to this model, the drug release from
these patches may be controlled by diffusion through the micropores. The remaining for-
mulations showed the best fit to the Korsmeyer-Peppas model. Formulations A1, A10,
B2, A32, B10 and B32 showed Fickian release, which is characterized by a linear depend-
ence of the released drug on the square root of time, which is concentration dependent.
Formulations A19 and B19 showed super case II transport drug release. This mechanism
could result from increased plasticization at the relaxing boundary. When swelling is pre-
dominant, drug diffusion probably occurs through the solvent-filled pathways of the
166
A. Puratchikody et al.: Development and characterization of mucoadhesive patches of salbutamol sulfate for unidirectional buccal





























0 10 20 30 40 50 60 70 80 90 100
A1 A10 A19 A32 B2 B10 B19 B32
110 120 130 140 150 160 170 180 190















A1 A10 A19 A32 B2 B10 B19 B32
Formulation code
Fig. 2. Ex vivo mucoadhesion time. Mean ± SD, n = 3.
swollen patch. Erosion of the matrix can also influence drug release from this polymer
matrix. A relative contribution of erosion and diffusion to the overall release mechanism
is suggested. Since all the polymers studied in these formulations were hydrophilic in
nature, we could not correlate the difference in the mechanism of drug release with the
polymer properties.
In vitro drug permeation
The drug permeation was fast and showed a similar profile to that of the in vitro
drug release. From formulation A10, 100 % of SS was permeated over a period of 60 min.
This finding was also in agreement with the swelling studies where A10 showed the ma-
ximum swelling index. Formulations A1, B2, B10 and B32 showed maximum drug per-
meation after 45 min, A10, A32 and A19 showed maximum drug permeation after 60
min, and A19 showed maximum drug permeation after 90 min. SS was released from
the formulations and permeated through the porcine buccal membrane and hence could
possibly permeate through the human buccal membrane as well. There was a good cor-
relation between the in vitro drug release and in vitro drug permeation results. The coef-
ficient of determination, R2 was > 0.994 for A1, A10, A19, A32, B2, B10, B19 and B32.
Accelerated stability studies and stability in human saliva
Accelerated stability study data of the medicated patches is shown in Table IV. Dur-
ing and at the end of the accelerated stability study, the tested patches showed non-sig-
nificantly different drug content from that observed at the beginning of the study. They
also showed satisfactory flexibility and elastic properties during and at the end of the ac-
celerated study period. We have conducted stability studies in normal human saliva to
appropriately mimic the drug and device stability in the oral cavity in vivo. No color
changes or unexpected changes in the texture were observed. The drug content of the
tested patches was in the range of 8.7 ± 0.5 and 9.6 ± 0.3 mg per 2 cm2 patch. The results
of stability studies indicated that there was no influence on the chemical and physical
stability of the formulations during the test period.
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Table III. R2, k and n for selected formulations
Formulation
Higuchi Korsmeyer-Peppas
Mechanism of drug release
R2 k (min–1/2) R2 n
A1 0.9811 0.2266 0.9833 0.3866 Fickian
A10 0.9985 1.6240 0.8013 1.2987 Diffusion/Fickian
A19 0.9754 2.2032 0.9974 1.3154 Super case II transport
A32 0.9981 1.6129 0.9846 0.8332 Diffusion/Fickian
B2 0.9853 0.2356 0.9892 0.4012 Fickian
B10 0.9918 1.5901 0.7701 1.3735 Diffusion/Fickian
B19 0.9773 2.2113 0.9834 1.3064 Super case II transport
B32 0.9058 1.7526 0.8982 0.8028 Diffusion/Fickian
CONCLUSIONS
Novel mucoadhesive buccal patches of SS with unidirectional drug delivery were
developed to overcome the first-pass metabolism and subsequent low bioavailability of
the salbutamol sulfate. The in vitro studies have shown that this is a potential drug de-
livery system for SS with a considerably good stability and release profile. Future stud-
ies are warranted to confirm these results in vivo.
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1st month 2nd month 3rd month 5th month 6th month
Drug (mg)a
A1 8.9 ± 0.7 8.9 ± 0.6 8.8 ± 0.5 8.8 ± 0.6 8.7 ± 0.5
A10 9.2 ± 0.5 9.1 ± 0.4 9.0 ± 0.5 9.0 ± 0.3 8.9 ± 0.2
A19 9.4 ± 0.6 9.3 ± 0.7 9.2 ± 0.5 9.1 ± 0.4 9.0 ± 0.5
A32 9.0 ± 0.3 8.9 ± 0.4 8.9 ± 0.2 8.8 ± 0.4 8.8 ± 0.2
B2 9.2 ± 0.6 9.2 ± 0.7 9.1 ± 0.5 9.0 ± 0.4 9.0 ± 0.5
B10 9.5 ± 0.2 9.5 ± 0.1 9.4 ± 0.2 9.3 ± 0.2 9.2 ± 0.1
B19 9.1 ± 0.5 9.1 ± 0.4 9.0 ± 0.3 9.0 ± 0.2 8.9 ± 0.4
B32 9.6 ± 0.3 9.5 ± 0.2 9.5 ± 0.4 9.4 ± 0.3 9.3 ± 0.2
Residence
timea
A1 108 ± 3 107 ± 4 106 ± 2 105 ± 4 103 ± 3
A10 104 ± 3 102 ± 3 102 ± 2 100 ± 4 100 ± 3
A19 118 ± 2 114 ± 2 113 ± 4 112 ± 3 111 ± 4
A32 115 ± 4 113 ± 2 112 ± 2 110 ± 2 109 ± 2
B2 123 ± 2 121 ± 3 120 ± 3 119 ± 2 119 ± 2
B10 129 ± 2 127 ± 4 126 ± 3 124 ± 2 122 ± 2
B19 121 ± 3 120 ± 4 120 ± 2 119 ± 4 118 ± 4
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S A @ E T A K
Razvoj i karakterizacija mukoadhezivnih flastera salbutamol
sulfata za jednosmjernu bukalnu isporuku
AYRIVAN PURATCHIKODY, VISWANADHAN VASANTHA PRASANTH,
SAM THOMAS MATHEW i BALARAMAN ASHOK KUMAR
U radu je opisana priprava flastera za bukalnu primjenu upotrebom razli~itih omje-
ra pet vodotopljivih polimera i PEG-400/PG kao plastifikatora. Potpuni 32 faktorijalni
dizajn upotrebljen je za dizajniranje eksperimenata za svaku kombinaciju polimera. Fla-
steri su postavljeni na jednu stranu usta s vodonepropusnom podlogom, koja omogu-
}ava jednosmjerno osloba|anje lijeka. Debljina flastera varirala je izme|u 0,2 i 0,4 nm.
Flasteri s PEG-400 bili su malo ve}e mase. pH na povr{ini svih flastera bio je blizu neu-
tralnog. Osam pripravaka vrlo otpornih na presavijanje (> 300) izabrano je za daljnju eva-
luaciju. Flasteri pripravljeni s PEG 400 imali su veliku sposobnost bubrenja. Flasteri su
se zadr`ali na mjestu primjene izme|u 105 i 130 min. Pripravci A10, A32, B10 i B32 naj-
bolje su slijedili Higuchijev model, dok su pripravci A19 i B19 pokazivali anomalno
osloba|anje koje ne slijedi Fickov zakon. Ispitivanje stabilnosti pokazalo je da ne postoje
promjene u kemijskim i fizikalnim svojstvima pripravaka tijekom 6 mjeseci.
Klju~ne rije~i: salbutamol sulfat, mukoadhezivni flasteri, bukalna isporuka, 32 potpuni faktorijalni
dizajn
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